Friday, July 10, 2026

Drug profile · INN

mecasermin rinfabate

mecasermin rinfabate (IPLEX) is a insulin-like growth factor i receptor agonist.

EMA: application withdrawn
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — mecasermin rinfabate
Class
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

mecasermin rinfabate (IPLEX) is a insulin-like growth factor i receptor agonist.

Key facts

INN mecasermin rinfabate
Brand IPLEX
Mechanism Insulin-like growth factor I receptor agonist
Target Insulin-like growth factor 1 receptor

Mechanism of action

Insulin-like growth factor I receptor agonist

Primary target: Insulin-like growth factor 1 receptor

Approval history

Authority Status Date
EMA application withdrawn

Pipeline programs

  1. Mecasermin rinfabate Phase 2 · Createrna Science and · Chronic Lung Disease
  2. rhIGF-I/rhIGFBP-3 Phase 2 · Takeda · Retinopathy of Prematurity (ROP)

Related & competitor drugs

  1. mecasermin Systemic hormonal preparations (H01)
  2. masoprocol Insulin-like growth factor I receptor inhibitor
  3. mecasermin recombinant Insulin-like growth factor I receptor agonist
  4. mecasermin rinfabate recombinant Insulin-like growth factor I receptor agonist
  5. teprotumumab-trbw Insulin-like growth factor I receptor antagonist
  6. teprotumumab Antineoplastic and immunomodulating agents (L04)

Frequently asked questions

What is mecasermin rinfabate?

mecasermin rinfabate (IPLEX) is a insulin-like growth factor i receptor agonist.

What is the brand name for mecasermin rinfabate?

IPLEX is a marketed brand name for mecasermin rinfabate. Check FDA Drugs@FDA for the current US label holder and prescribing information.